← Leaderboards
Andrew Carl Dudley
Boston Children'S Hospital
$7,192,909
Attributed
$9,415,057
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,415,057 · 5
By mechanism
R01$6,852,321 · 2
T32$1,566,368 · 1
R00$732,060 · 1
K99$264,308 · 1
Top collaborators
- Chad V Pecot5 shared
- Melanie R Rutkowski3 shared
- Amy H Bouton1 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Qian Yin$3,865,320
- Lois Smith$17,647,467
- Fan Zhang$1,043,550
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsEndothelial CellsTumorCellsNeoplastic CellTumor GrowthMediatingGeneticNeoplasm MetastasisHeterogeneityTumor ProgressionNeoplasms In Vascular TissueMouse ModelCell LineTumor MicroenvironmentImmuneRecruitMolecularImmune Checkpoint BlockadeAngiogenesis InhibitorsSolid NeoplasmGrowthBreast Cancer ModelIn Vivo
Grant awards (26)
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$580,098
R01 · FY2025 · CA
Targeting the vasculature to enhance anti-tumor immunity$547,081
R01 · FY2025 · CA · contact PI
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies$402,263
T32 · FY2025 · CA · contact PI
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$551,095
R01 · FY2024 · CA
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies$424,585
T32 · FY2024 · CA · contact PI
Targeting the vasculature to enhance anti-tumor immunity$345,206
R01 · FY2024 · CA · contact PI
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$568,496
R01 · FY2023 · CA
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies$427,685
T32 · FY2023 · CA · contact PI
Targeting the vasculature to enhance anti-tumor immunity$389,460
R01 · FY2023 · CA · contact PI
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$568,496
R01 · FY2022 · CA
Targeting the vasculature to enhance anti-tumor immunity$356,108
R01 · FY2022 · CA · contact PI
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies$311,835
T32 · FY2022 · CA · contact PI
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$609,743
R01 · FY2021 · CA
Targeting the vasculature to enhance anti-tumor immunity$363,375
R01 · FY2021 · CA · contact PI
Targeting the vasculature to enhance anti-tumor immunity$363,375
R01 · FY2020 · CA · contact PI
Mechanisms of tumor escape from anti-angiogenic therapy$331,616
R01 · FY2018 · CA · contact PI
Mechanisms of tumor escape from anti-angiogenic therapy$330,775
R01 · FY2017 · CA · contact PI
Mechanisms of tumor escape from anti-angiogenic therapy$290,457
R01 · FY2016 · CA · contact PI
Mechanisms of tumor escape from anti-angiogenic therapy$31,386
R01 · FY2016 · CA · contact PI
Mechanisms of tumor escape from anti-angiogenic therapy$312,777
R01 · FY2015 · CA · contact PI
Mechanisms of tumor escape from anti-angiogenic therapy$312,777
R01 · FY2014 · CA · contact PI
Tumor endothelial cell abnormalities$234,060
R00 · FY2013 · CA · contact PI
Tumor endothelial cell abnormalities$249,000
R00 · FY2012 · CA · contact PI
Tumor endothelial cell abnormalities$249,000
R00 · FY2011 · CA · contact PI
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi$133,628
K99 · FY2010 · CA · contact PI
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi$130,680
K99 · FY2009 · CA · contact PI